Hard to Treat Diseases (Hard to Treat Diseases) Operating Cash Flow per Share : $ (TTM As of . 20)

View and export this data going back to . Start your Free Trial

What is Hard to Treat Diseases Operating Cash Flow per Share?

Hard to Treat Diseases's operating cash flow per share for the three months ended in . 20 was $0.00. Hard to Treat Diseases does not have enough years/quarters to calculate the operating cash flow per share for the trailing twelve months (TTM) ended in . 20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Hard to Treat Diseases's Operating Cash Flow per Share or its related term are showing as below:

HTDS's 3-Year OCF Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.3
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

Hard to Treat Diseases Operating Cash Flow per Share Historical Data

The historical data trend for Hard to Treat Diseases's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hard to Treat Diseases Operating Cash Flow per Share Chart

Hard to Treat Diseases Annual Data

Trend

Operating Cash Flow per Share

Hard to Treat Diseases Quarterly Data

Operating Cash Flow per Share

Competitive Comparison of Hard to Treat Diseases's Operating Cash Flow per Share

For the Biotechnology subindustry, Hard to Treat Diseases's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hard to Treat Diseases's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hard to Treat Diseases's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Hard to Treat Diseases's Price-to-Operating-Cash-Flow falls into.

Hard to Treat Diseases Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Hard to Treat Diseases's Operating Cash Flow per Share for the fiscal year that ended in . 20 is calculated as

Operating Cash Flow per Share (A: . 20 )	=	Cash Flow from Operations (A: . 20 )	/	Shares Outstanding (Diluted Average) (A: . 20 )
	=		/	0
	=

Hard to Treat Diseases's Operating Cash Flow per Share for the quarter that ended in . 20 is calculated as

Operating Cash Flow per Share (Q: . 20 )	=	Cash Flow from Operations (Q: . 20 )	/	Shares Outstanding (Diluted Average) (Q: . 20 )
	=		/	0
	=

Hard to Treat Diseases Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Hard to Treat Diseases's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Hard to Treat Diseases (Hard to Treat Diseases) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hard to Treat Diseases Inc (OTCPK:HTDS) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

2655 Ulmerton Road, No. 338, Clearwater, FL, USA, 33762

Website

http://www.htdsmedical.com

Hard to Treat Diseases Inc operates medical and cosmetics company in Europe, and Mainland China. It is s also in the process of developing its own stem cell bank.

Hard to Treat Diseases (Hard to Treat Diseases) Headlines

No Headlines